Treatment with the targeted agent tucatinib appears to reduce the risk of death or the risk of progression of brain metastases in patients diagnosed with advanced breast cancer when compared with patients just treated with trastuzumab and capecitabine, researchers reported at the ASCO 2020 virtual meeting. The risk of experiencing the composite primary endpoint was ...
Breast cancer brain metastases treated with tucatinib
By Edward Susman
5 Jun 2020